BioSpace News Archive

Kinarus Therapeutics Holding AG announced the signing of subordinated bridge loan agreements with existing shareholders to ensure further liquidity is available to Kinarus during the period of time required for bridging the pending transfer of funds pursuant to a CHF1.5 million convertible loan investment from ChaoDian Investment Management Co, in Kinarus.

Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.

Luciole Medical AG, a Swiss medical technology company specialized in brain monitoring, announced the acquisition of Spiegelberg GmbH & Co. KG, an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital.

Xentria Inc. and Meitheal Pharmaceuticals, Inc. announced an exclusive multi-year licensing agreement to commercialize its lead candidate, and novel biologic, XTMAB-16 for pulmonary sarcoidosis in North America.

Verona Pharma plc announces the submission of a New Drug Application to the US Food and Drug Administration for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease.

Mestag Therapeutics and VIB announced entering into an agreement under which Mestag obtains the exclusive worldwide rights to research, develop and commercialize a panel of single domain antibodies, also known as Nanobodies®, to an undisclosed target that plays a central role in anti-cancer immunity.

Allecra Therapeutics announced the submission of a New Drug Application to the U.S. Food and Drug Administration for cefepime/enmetazobactam, an antibiotic combination of the fourth generation cephalosporin cefepime with the proprietary beta lactamase inhibitor, enmetazobactam, for the treatment of complicated urinary tract infections.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that the large multi-center observational registry study INSIGHT has completed enrollment of 5,000 patients with non-small cell lung cancer.

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its wholly-owned anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer’s disease.

First Wave BioPharma, Inc. today announced the publication of two patent applications for composition of matter and methods of use claims governing the Company’s enhanced enteric microgranule delivery formulation of adrulipase.